盐酸奈必洛尔 T0154
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 7
- 0
Product IntroductionBioactivity英文名: Nebivolol hydrochloride描述: Nebivolol hydrochloride (R 065824 hydrochloride) 是一种β1-肾上腺
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Nebivolol hydrochloride
描述: Nebivolol hydrochloride (R 065824 hydrochloride) 是一种β1-肾上腺素受体选择性抑制剂，IC50为0.8 nM。
细胞实验: Cells are exposed to different concentrations of Nebivolol (10-7~10-5 M) for 1, 2, 4, 7 and 14 days. Cell proliferation is analyzed by bromodeoxyuridine (BrdU) incorporation, and cell apoptosis is detected by PI or annexin V staining.(Only for Reference)
体外活性: Nebivolol处理患心肌梗塞大鼠,少量降低平均血压.开始静脉注射Nebivolol 10分钟,然后再口服处理患有心肌梗塞的大鼠,可以降低心肌凋亡.
体内活性: Nebivolol可以降低冠状动脉平滑肌细胞(haCSMCs)及内皮细胞(haECs)增殖,这种作用存在浓度和时间依赖性。Nebivolol在制备兔肺膜时,作用于beta 1-肾上腺素受体位点具有高亲和性和高度选择性。Nebivolol处理haCSMCs7天,明显抑制细胞增殖（IC50：6.1 μM）。Nebivolol处理haCSMCs 48小时,细胞凋亡率23%,且降低S期细胞数量。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 4.4 mg/mL (10 mM)
DMSO : 44.2 mg/mL (100 mM)
关键字: R-065824 Hydrochloride | adrenergic blocking | Adrenergic Receptor | ischemic heart disease | R65824 | R 065824 | congestive heart failure | coronary artery disease | R065824 | Nebivolol | oral | inhibit | hypertension | R 065824 Hydrochloride | Nebivolol hydrochloride | Inhibitor | R065824 Hydrochloride | Beta Receptor | vasodilator | R 65824 | Apoptosis | R-065824 | Nebivolol Hydrochloride
相关产品: S-allyl-L-cysteine | Daunorubicin hydrochloride | ATH686 | 5-LOX-IN-2 | Docetaxel trihydrate | Melatonin | Phenoxodiol | Diatrizoic Acid | SU9516 | WYC-209
相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library | Anti-Cancer Approved Drug Library | Highly Selective Inhibitor Library
Bioactivity
英文名: Nebivolol hydrochloride
描述: Nebivolol hydrochloride (R 065824 hydrochloride) 是一种β1-肾上腺素受体选择性抑制剂，IC50为0.8 nM。
细胞实验: Cells are exposed to different concentrations of Nebivolol (10-7~10-5 M) for 1, 2, 4, 7 and 14 days. Cell proliferation is analyzed by bromodeoxyuridine (BrdU) incorporation, and cell apoptosis is detected by PI or annexin V staining.(Only for Reference)
体外活性: Nebivolol处理患心肌梗塞大鼠,少量降低平均血压.开始静脉注射Nebivolol 10分钟,然后再口服处理患有心肌梗塞的大鼠,可以降低心肌凋亡.
体内活性: Nebivolol可以降低冠状动脉平滑肌细胞(haCSMCs)及内皮细胞(haECs)增殖,这种作用存在浓度和时间依赖性。Nebivolol在制备兔肺膜时,作用于beta 1-肾上腺素受体位点具有高亲和性和高度选择性。Nebivolol处理haCSMCs7天,明显抑制细胞增殖（IC50：6.1 μM）。Nebivolol处理haCSMCs 48小时,细胞凋亡率23%,且降低S期细胞数量。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 4.4 mg/mL (10 mM)
DMSO : 44.2 mg/mL (100 mM)
关键字: R-065824 Hydrochloride | adrenergic blocking | Adrenergic Receptor | ischemic heart disease | R65824 | R 065824 | congestive heart failure | coronary artery disease | R065824 | Nebivolol | oral | inhibit | hypertension | R 065824 Hydrochloride | Nebivolol hydrochloride | Inhibitor | R065824 Hydrochloride | Beta Receptor | vasodilator | R 65824 | Apoptosis | R-065824 | Nebivolol Hydrochloride
相关产品: S-allyl-L-cysteine | Daunorubicin hydrochloride | ATH686 | 5-LOX-IN-2 | Docetaxel trihydrate | Melatonin | Phenoxodiol | Diatrizoic Acid | SU9516 | WYC-209
相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library | Anti-Cancer Approved Drug Library | Highly Selective Inhibitor Library
猜你喜欢
感兴趣产品